OakChart

Nexgel Inc

NXGLHealthcare·Medical Instruments & Supplies·USA·Nano·NASD·Nov 11 • 9:01 AM ET

3.96+0.38 (10.61%)
2026-11-11 15:21 CET
Market cap
1.74 USD m
Revenue, TTM
12.07 USD m
Net income, TTM
-6.18 USD m
Free cash flow, TTM
-3.34 USD m
EPS diluted, TTM
-14.35
P/E
-
Compare

Price

NXGL against its 20, 50 and 200-day averages
2050200miss
10.0020.0030.001.7M3.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NXGLclose 3.9620-day 4.3950-day 4.63200-day 11.393.96

92.6% under 53.60 on 6 Nov 2025. Last 15 sessions, 64.7% high to low

Profile

NXGL
52-week range, 2% of the way up
3.0048.80

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It operates through the NexGel and CGN segments. The NexGel segment consists of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. The CGN segment consists of the CGN JV used for the company's converting and packaging business, which is based in Granbury, Texas. The company was founded on January 13, 2009, and is headquartered in Langhorne, PA.

Employees19
IPODec 22, 2021
Beta0.79
ATR, 14d0.66
Rel volume0.06
Short float5.73%
Insider own14.08%
Inst own5.98%

Snapshot

6 groups

Valuation

Index-
Market Cap12.17M
Enterprise Value18.44M
Income-6.18M
Sales12.07M
Book/sh10.20
Cash/sh0.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees19
IPODec 22, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1.01
P/B0.39
P/C7.12
P/FCF-
EV/EBITDA-
EV/Sales1.53
Quick Ratio0.27
Current Ratio0.43
Debt/Eq1.51
LT Debt/Eq1.32
Option/ShortNo / Yes

Earnings

EPS (ttm)-14.35
EPS next Y-4.40
EPS next Q-4.80
EPS this Y-147.37%
EPS next Y76.60%
EPS next 5Y49.14%
EPS past 3/5Y23.45% -77.45%
Sales past 3/5Y77.33% 76.12%
EPS Y/Y TTM-78.48%
Sales Y/Y TTM3.38%
EPS Q/Q-364.19%
Sales Q/Q27.81%
EarningsAug 14 BMO
EPS/Sales Surpr.-233.33% -14.58%

Ownership

Insider Own14.08%
Insider Trans-7.48%
Inst Own5.98%
Inst Trans-
ROA-34.21%
ROE-128.59%
ROIC-53.83%
Gross Margin34.73%
Oper. Margin-44.77%
Profit Margin-51.26%
SMA20-9.78%
SMA50-14.39%
SMA200-65.24%
Trades-

Technical

Shs Outstand0.49M
Shs Float0.42M
Short Float5.73%
Short Ratio0.21
Short Interest0.02M
52W High48.80 -91.89%
52W Low3.00 32.00%
Volatility13.65% 18.93%
ATR (14)0.66
RSI (14)46.40
Beta0.79
Rel Volume0.06
Avg Volume113.44K
Volume364

Performance

Perf Week-1.25%
Perf Month-2.22%
Perf Quarter-59.48%
Perf Half Y-62.85%
Perf YTD-87.70%
Perf Year-91.32%
Perf 3Y-88.49%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price40.00
Prev Close3.58
Price3.96
Change %10.61%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Aug 24, 2026DowngradeMMaxim GroupBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
CUPRCuprina Holdings (Cayman) Ltd9.43M
SMTISanara MedTech Inc290.89M
RGNTRegentis Biomaterials Ltd9.27M
RVPRetractable Technologies Inc16.62M
NEPHNephros Inc34.24M
FEMYFemasys Inc11.98M
MLSSMilestone Scientific Inc26.46M
DXRDaxor Corp49.82M
HBIOHarvard Bioscience Inc42.15M
POCIPrecision Optics Corp Inc55.74M

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Levy Adam R.AffilaiteSep 29 '26Proposed Sale0.1621,5003,489Sep 30 01:33 PM
Levy Adam R.Chief Executive OfficerJun 18 '26Sale0.596,0003,553327,692Jun 23 07:51 PM
Levy Adam R.Chief Executive OfficerJun 23 '26Sale0.595,0002,967322,692Jun 23 07:51 PM
Levy Adam R.Chief Executive OfficerJun 11 '26Sale0.613,0001,841333,692Jun 15 05:39 PM
Levy Adam R.Chief Executive OfficerJun 04 '26Sale0.593,0001,781339,692Jun 09 07:17 PM
Levy Adam R.Chief Executive OfficerJun 08 '26Sale0.553,0001,641336,692Jun 09 07:17 PM
Levy Adam R.Chief Executive OfficerJun 01 '26Sale0.592,0001,172342,692Jun 03 06:53 PM
Levy Adam R.Chief Executive OfficerMay 28 '26Sale0.617,0004,241347,692May 29 08:03 PM
Levy Adam R.Chief Executive OfficerMay 29 '26Sale0.603,0001,801344,692May 29 08:03 PM
Levy Adam R.Chief Executive OfficerMay 27 '26Sale0.603,0001,792354,692May 29 08:03 PM
Levy Adam R.OfficerMay 27 '26Proposed Sale0.5450,00027,065May 27 10:43 AM
Levy Adam R.Chief Executive OfficerDec 22 '25Sale1.616,0009,661361,692Dec 29 08:47 AM
Levy Adam R.Chief Executive OfficerDec 24 '25Sale1.574,0006,286357,692Dec 29 08:47 AM
Levy Adam R.OfficerDec 22 '25Proposed Sale1.6410,00016,400Dec 22 11:24 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
DFMCU.S. Micro Cap Portfolio ETF Class Shares-

News

latest 14 of 103
  • NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding (GlobeNewswire) +10.61%
  • NEXGEL Regains Compliance with Nasdaq Listing Requirement (GlobeNewswire) +7.45%
  • NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness (GlobeNewswire)
  • NEXGEL Announces Dial-In Details for Investor Update Call (GlobeNewswire)
  • NEXGEL Announces Date for Investor Update Call (GlobeNewswire) -11.70%
  • Loading…
  • NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE (GlobeNewswire) -14.79%
  • NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp (InvestorsHub) -33.54%
  • NEXGEL Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th -18th (GlobeNewswire)
  • NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration (GlobeNewswire) +20.14%
  • NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical (GlobeNewswire) -8.10%
  • NEXGEL To Report First Quarter 2026 Financial Results on May 15th (GlobeNewswire)
  • NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience, to Board of Directors (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-8.000-2.400-8.0003.694.321
2026Q12026-05-14-2.200-1.400-2.2602.653.911
2025Q42026-03-31-2.400-1.800-2.3822.803.241
2025Q32025-11-11-1.600-1.600-1.6382.933.161
2025Q22025-08-12-1.800-1.400-1.7382.883.081
2025Q12025-05-13-1.800-2.000-1.8632.812.731
2024Q42025-03-24-2.200-2.600-2.3283.042.991
2024Q32024-11-13-2.200-2.000-2.1102.942.851
2024Q22024-08-14-2.800-2.800-2.8301.441.401
2024Q12024-05-13-2.800-3.600-2.8521.271.211
2023Q42024-04-01-3.800-2.200-3.8251.101.101
2023Q32023-11-13-2.000-2.400-1.9251.221.201
2023Q22023-08-14-2.400-2.600-2.4551.171.001
2023Q12023-05-15-3.000-2.800-2.8890.620.451
2022Q42023-03-27-2.200-3.000-2.3230.520.601
2022Q32022-11-08-4.400-2.600-4.4040.570.591

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-29.000-1.000-15.4701.551.44
2022FY-17.000-17.600-17.0272.052.12
2023FY-11.200-9.400-11.1324.094.11
2024FY-10.000-10.800-10.0778.698.64
2025FY-7.600-7.000-7.60011.4211.86
2026FY--18.800--15.79
2027FY--4.400--24.27
2028FY--1.000--26.11
2029FY-0.000--28.17
2030FY-0.400--29.73

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-041004.194.194.19
2026Q3S2026-08-211014.194.194.19
2026Q3S2026-08-171006.906.906.90
2026Q3S2026-08-141006.906.906.90
2026Q3S2026-07-291006.906.906.90
2026Q3S2026-05-181016.906.906.90
2026Q3S2026-05-151016.906.906.90
2026Q3S2026-05-141009.649.649.64
2026Q3S2026-04-291009.649.649.64
2026Q3S2026-04-281009.649.649.64
2026Q3R2026-11-04100-4.80-4.80-4.80
2026Q3R2026-08-21101-4.80-4.80-4.80
2026Q3R2026-08-17100-0.04-0.04-0.04
2026Q3R2026-08-14100-0.80-0.80-0.80

Estimate history

EPS, annual-7.544-2.834-0.434-15.47-17.027-11.132-10.077-7.639-14.3464
Period20182019202020212022202320242025TTM
EPS, quarterly-2.83-2.11-2.328-1.863-1.738-1.638-2.382-2.26-8.066
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.2130.7170.6741.5512.0484.0898.68811.42112.07
Period20182019202020212022202320242025TTM
Sales, quarterly1.442.943.0412.8062.8842.9342.7962.653.686
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.8752.8755.2140.2790.2790.2870.3820.4070.485
Period20182019202020212022202320242025MRQ
Shares, quarterly0.3160.340.3820.3830.3830.4070.4070.4240.485
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue12.0711.428.694.092.051.550.670.722.21
Cost of Goods Sold Incl. D&A7.886.916.103.601.811.550.980.881.73
Gross Profit4.194.512.590.490.24-0.00-0.30-0.160.48
Selling, General and Administrative Excl. Other9.597.866.153.973.592.571.961.762.37
Research and Development-0.000.080.100.370.03---
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-5.40-3.35-3.55-3.48-3.35-2.57-2.26-1.92-1.89
Interest Expense-0.030.080.011.342.000.010.000.00
Unusual Expense-1.03-0.12-0.01-0.100.07-0.260.00-0.000.00
Net Income Before Taxes-6.05-2.89-3.46-3.19-4.75-4.31-2.26-1.92-1.89
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-6.05-2.89-3.46-3.19-4.75-4.31-2.26-1.92-1.89
Net Income From Continuing Operations-6.18-3.00-3.28-3.16-4.75-4.31-2.26-1.92-1.89
Net Income-6.18-3.00-3.28-3.16-4.75-4.31-2.26-1.92-1.89
EPS (Recurring)-15.32-7.85-10.10-11.37-16.86-16.12-0.43-2.84-7.54
EPS (Basic, Before Extraordinaries)-14.35-7.64-10.08-11.13-17.03-15.47-0.43-2.83-7.54
EPS (Diluted)-14.35-7.64-10.08-11.13-17.03-15.47-0.43-2.83-7.54
EBITDA-3.73-2.61-3.07-3.03-3.05-2.46-2.21-1.86-1.57
Non-Operating Income (Expense)0.590.380.160.210.000.000.010.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.620.650.360.200.280.280.230.000.21
Price To Sales Ratio0.371.113.342.953.409.38---
Gross Margin34.7339.4829.8312.0611.72-0.26-45.10-22.4521.92
Operating Margin-44.77-29.35-40.91-85.03-163.48-165.70-335.31-268.34-85.31
Net Margin-51.26-26.27-37.76-77.21-231.74-277.89-335.91-268.20-85.31
Shares Outstanding0.490.410.380.290.280.285.212.882.88
Market Capitalization1.741.7434.0730.97-----

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue3.692.652.802.932.882.813.042.94
Cost of Goods Sold Incl. D&A2.581.591.981.731.671.662.311.69
Gross Profit1.111.060.821.201.221.150.731.25
Selling, General and Administrative Excl. Other3.612.022.031.931.851.921.572.04
Research and Development0.020.00-0.010.000.00-0.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.50-0.96-1.21-0.72-0.64-0.78-0.84-0.79
Interest Expense2.230.040.00-0.020.020.010.02
Unusual Expense-1.010.00-0.01-0.01-0.01-0.090.03-0.01
Net Income Before Taxes-3.61-0.87-0.93-0.65-0.64-0.68-0.82-0.75
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.61-0.87-0.93-0.65-0.64-0.68-0.82-0.75
Net Income From Continuing Operations-3.63-0.93-0.97-0.65-0.67-0.71-0.85-0.69
Net Income-3.63-0.93-0.97-0.65-0.67-0.71-0.85-0.69
EPS (Recurring)-9.64-2.26-2.39-1.65-1.76-2.03-2.28-2.13
EPS (Basic, Before Extraordinaries)-8.07-2.26-2.38-1.64-1.74-1.86-2.33-2.11
EPS (Diluted)-8.07-2.26-2.38-1.64-1.74-1.86-2.33-2.11
EBITDA-1.52-0.79-0.81-0.61-0.53-0.65-0.73-0.61
Non-Operating Income (Expense)0.110.130.280.070.000.030.060.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.120.140.150.200.130.170.100.15
Price To Sales Ratio0.370.461.151.671.692.233.752.52
Gross Margin30.0940.0429.2940.9342.1640.8424.1042.69
Operating Margin-67.96-36.15-43.42-24.71-22.05-27.69-27.66-26.80
Net Margin-98.62-34.98-34.69-22.26-23.06-25.37-27.95-23.57
Shares Outstanding0.490.420.410.410.380.380.380.34
Market Capitalization1.745.3713.1119.8719.7522.8134.0730.97

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments1.061.812.706.6113.350.030.260.00
Short Term Receivables0.670.930.630.220.210.070.100.03
Inventories2.111.751.320.500.290.230.110.10
Other Current Assets0.500.620.400.170.080.030.040.23
Total Current Assets4.345.115.057.5013.930.360.510.36
Net Property, Plant & Equipment3.973.843.352.462.651.361.200.20
Total Investments and Advances0.250.000.000.000.000.000.000.00
Intangible Assets1.811.941.450.330.340.36--
Other Assets0.100.100.100.060.060.180.180.18
Total Assets10.4610.989.9610.3616.982.261.890.74
Short Term Debt Incl. Current Port. of LT Debt0.470.390.560.222.250.420.210.00
Accounts Payable1.291.291.230.270.250.660.510.16
Other Current Liabilities1.190.790.760.370.380.250.080.25
Total Current Liabilities2.962.472.550.862.891.330.800.41
Long Term Debt2.612.432.241.862.010.850.710.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.05
Total Liabilities5.574.904.792.724.902.191.510.46
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity4.465.754.707.6412.090.070.380.28
Total Shareholders Equity4.465.754.707.6412.090.070.380.28
Accumulated Minority Interest0.430.330.470.000.000.000.000.00
Total Equity4.896.085.177.6412.090.070.380.28
Total Liabilities & Stockholders Equity10.4610.989.9610.3616.982.261.890.74
Book Value Per Share10.9515.0716.3627.3843.380.010.130.10
Tangible Book Value Per Share6.5110.0011.3026.2042.14-0.060.130.10
Full-Time Employees191919121086-
Price to Book Ratio0.355.926.61-----
Return on Assets-27.98-31.34-31.09-34.72-44.80-109.19-146.29-
Return on Equity-58.74-62.78-51.19-48.13-70.91-1,003.99-581.85-
Return on Invested Capital-42.41-40.07-45.51-49.97-30.58-244.76-176.42-671.89
Quick Ratio0.751.361.468.154.720.100.500.64
Current Ratio1.472.071.988.744.820.270.640.89

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-5.99-2.89-3.28-3.16-4.75-4.31-2.26-1.92-1.89
Depreciation1.670.740.480.440.300.110.050.070.32
Other Funds (Non Cash)1.270.370.11-0.101.692.040.240.00-0.01
Funds from Operations-3.06-1.78-2.70-2.81-2.76-2.16-1.98-1.85-1.58
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.150.47-1.17-0.42-0.23-0.590.180.040.04
Cash from Operating Activities-3.21-1.31-3.87-3.24-2.99-2.75-1.80-1.81-1.54
Capital Expenditures-0.13-0.07-0.44-0.70-0.10-0.27-0.310.000.00
Net Assets From Acquisitions-6.500.00-0.40-0.550.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.040.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.075.70-5.500.000.000.000.00
Purchase of Investments0.000.000.000.00-7.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.075.701.500.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.63-0.07-0.744.46-5.59-0.27-0.310.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.960.963.770.000.0013.471.370.730.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.960.963.770.000.0013.471.370.730.00
Proceedsfrom Stock Options0.960.963.770.000.0013.471.370.730.00
Issuance or Reduction of Debt, Net10.04-0.160.220.55-3.512.870.510.000.00
Change in Long Term Debt10.04-0.16-0.130.310.00-0.120.510.000.00
Issuance of Long Term Debt10.200.000.000.320.00-0.100.510.000.00
Reduction of Long Term Debt-0.16-0.16-0.13-0.010.00-0.010.000.000.00
Net Financing Active Other Cash Flow-0.18-0.18-0.28-0.17-0.150.000.001.341.54
Other Financing Activities Uses-0.18-0.18-0.28-0.17-0.150.000.000.000.00
Cash from Financing Activities10.820.633.710.38-3.6616.341.882.081.54
Net Change in Cash0.98-0.75-0.891.60-12.2513.32-0.230.260.00
Free Cash Flow-3.34-1.38-4.31-3.93-3.09-3.02-2.11-1.81-1.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.712.121.061.860.721.19
Short Term Receivables1.080.660.670.840.750.93
Inventories2.302.262.112.021.821.85
Other Current Assets1.080.590.500.890.860.78
Total Current Assets6.175.644.345.604.164.74
Net Property, Plant & Equipment5.313.833.974.083.583.70
Total Investments and Advances0.250.250.250.000.000.00
Intangible Assets14.621.781.811.841.871.90
Other Assets0.100.100.100.100.100.10
Total Assets26.4511.6010.4611.629.7110.44
Short Term Debt Incl. Current Port. of LT Debt0.920.480.470.460.400.39
Accounts Payable3.921.811.291.221.271.48
Other Current Liabilities9.601.021.191.640.730.65
Total Current Liabilities14.443.312.963.312.402.52
Long Term Debt6.543.802.612.742.262.35
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities20.987.125.576.044.664.87
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.953.994.465.194.675.21
Total Shareholders Equity4.953.994.465.194.675.21
Accumulated Minority Interest0.520.490.430.390.380.36
Total Equity5.474.484.895.585.055.57
Total Liabilities & Stockholders Equity26.4511.6010.4611.629.7110.44
Book Value Per Share10.209.4210.9512.7412.2013.61
Tangible Book Value Per Share-19.945.226.518.227.318.64
Full-Time Employees--19---
Price to Book Ratio0.351.342.943.834.234.38
Return on Assets-34.21-29.18-27.98-25.96-29.97-30.16
Return on Equity-128.59-69.87-58.74-58.34-66.08-62.82
Return on Invested Capital-31.64-11.89-13.71-8.24-9.59-9.42
Quick Ratio0.271.020.751.080.981.15
Current Ratio0.431.701.471.691.741.88

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.61-0.87-0.86-0.65-0.67-0.71
Depreciation0.980.170.400.110.100.13
Other Funds (Non Cash)1.010.15-0.100.200.160.11
Funds from Operations-1.62-0.55-0.56-0.34-0.41-0.48
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.580.040.84-0.45-0.000.08
Cash from Operating Activities-2.20-0.500.28-0.79-0.41-0.40
Capital Expenditures-0.08-0.01-0.04-0.01-0.020.00
Net Assets From Acquisitions-6.500.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-6.58-0.01-0.04-0.01-0.020.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-1.001.960.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-1.001.960.000.00
Proceedsfrom Stock Options0.000.00-1.001.960.000.00
Issuance or Reduction of Debt, Net8.541.58-0.04-0.04-0.04-0.04
Change in Long Term Debt8.541.58-0.04-0.04-0.04-0.04
Issuance of Long Term Debt8.591.620.000.000.000.00
Reduction of Long Term Debt-0.04-0.04-0.04-0.04-0.04-0.04
Net Financing Active Other Cash Flow-0.180.000.000.000.00-0.18
Other Financing Activities Uses-0.180.000.000.000.00-0.18
Cash from Financing Activities8.361.58-1.041.93-0.04-0.21
Net Change in Cash-0.421.06-0.801.13-0.47-0.61
Free Cash Flow-2.27-0.510.24-0.79-0.43-0.40

Revenue breakdown

United States2024: 8.69M 2025: 11.42M
Branded Consumer Products2024: 5.48M
Contract Manufacturing2024: 2.84M
Custom and White Label Finished Goods2024: 42.00K
Other Incomes2024: 322.00K
Total Surgical & Medical Instruments & Apparatus revenue2025: 11.42M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.73%0.0M0.4M110.64K
2026-10-1524.94%0.1M0.4M103.16K
2026-09-303.85%0.0M0.4M36.48K
2026-09-152.36%0.0M0.4M38.66K
2026-08-314.77%0.0M0.4M37.22K
2026-08-143.33%0.0M0.4M15.73K
2026-07-311.72%0.0M0.4M12.08K
2026-07-152.25%0.0M0.4M16.66K
2026-06-302.32%0.0M0.4M16.27K
2026-06-150.57%0.0M0.4M10.66K
2026-05-291.55%0.0M0.3M19.84K
2026-05-152.84%0.0M0.3M18.83K
2026-04-305.09%0.0M0.3M18.53K
2026-04-151.88%0.0M0.3M14.21K
2026-03-311.20%0.0M0.4M13.18K
2026-03-132.93%0.0M0.3M12.33K
2026-02-270.06%0.0M0.3M2.73K
2026-02-130.04%0.0M0.3M3.07K
2026-01-300.02%0.0M0.3M3.42K
2026-01-150.13%0.0M0.3M3.73K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-078-KCurrent report2026-10-07SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-08-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-24SEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-20S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-1710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-17NT 10-Q2026-06-30SEC
2026-08-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-08-058-KCurrent report2026-07-31SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-23SEC
2026-07-298-KCurrent report2026-07-23SEC
2026-07-098-KCurrent report2026-07-09SEC
2026-07-028-KCurrent report2026-06-29SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-09DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-09SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-29SEC
2026-05-27144Filing for proposed sale of securities under Rule 144.SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-06SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060012.95K6
2026-05007.83K3
2026-040000
2026-030000
2026-020000
2026-010000
2025-120015.95K2
2025-110010.08K1

Institutional holders

Manager% owned
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.92%
Virtu Financial LLC0.86%
HRT FINANCIAL LP0.75%
GEODE CAPITAL MANAGEMENT, LLC0.73%
MORGAN STANLEY0.60%
VANGUARD CAPITAL MANAGEMENT LLC0.53%
CITADEL ADVISORS LLC0.44%
VANGUARD FIDUCIARY TRUST CO0.37%
UBS Group AG0.27%
JANE STREET GROUP, LLC0.22%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.53%
Fidelity Extended Market Index Fund0.46%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.01%
U.S. MICRO CAP PORTFOLIO0.00%
U.S. SMALL CAP PORTFOLIO0.00%
Dimensional U.S. Small Cap ETF0.00%

OakChart. NXGL. Cached 15 minutes.